Description
-
Randomised double-blinded, placebo controlled, parallel-group study
-
2 treatment groups
-
AZD0780
-
Placebo
-
-
Trial medication will be taken once daily in ADDITION to your current lipid-lowering medication
-
Participants will be required to continue on stable doses of their maintenance therapy (standard of care) throughout the study to minimise the risk of disease worsening during the study
-
Trial length
56 weeks
Participant age
Participant must be ages 18+
Patient eligibility
-
Participants must have a history of clinical ASCVD or at risk for a first ASCVD event
-
Participants should be receiving a maximally tolerated lipid-lowering regimen including a maximally tolerated dose of a statin or have documented intolerable side effects to at least 2 different statins
-
Participants must NOT have uncontrolled severe hypertension
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
-
Participants must NOT have known history of alcohol and/or drug abuse within 5 years prior to screening
-
Participants must NOT have uncontrolled type 2 diabetes
10 onsite visits
*Travel is reimbursed for each visit
** Please contact site for further information regarding eligibility
Study Requirements
Objectives
To assess the effect of the medication AZD0780 on low-density lipoprotein cholesterol (LDL-C) in patients with elevated cholesterol and have had clinical atherosclerotic cardiovascular disease (ASCVD) or are at risk for a first ASCVD event
Get in touch with us
Our friendly team would love to hear from you!